Compare Norfolk Southern Corporation (NSC) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Novavax Inc — how do they compare? Norfolk Southern Corporation trades at $316.97 (market cap $71.20B), while Novavax Inc trades at $12.33 (market cap $1.82B). The key difference: Norfolk Southern Corporation is far larger — about 39.1× Novavax Inc's market cap, and Norfolk Southern Corporation pays a 1.7% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Norfolk Southern Corporation for 33 Days and Novavax Inc for 59 Days on average.
| NSC | NVAX | |
|---|---|---|
Market Cap | $71.20B | $1.82B |
Volume | 555,248 | 6,198,505 |
Sector | Industrials | Health |
52-Week High | $352.98 | $12.56 |
52-Week Low | $278.19 | $6.22 |
Typical Hold Time | 33 Days | 59 Days |
Enterprise Value | $86.75B | $1.39B |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $317.14, up 1.26% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $361.86. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Strong profitability is evidenced by a 21.02% net income margin and 16.97% ROE, while news highlights significant institutional investment and progress on the proposed merger with Union Pacific.
The outlook is positive, supported by earnings momentum and potential merger benefits, but risks include integration challenges, fuel cost pressures noted in recent news, and a relatively high P/E ratio of 27.05. The stock offers a dividend yield and growth potential, contingent on successful execution of strategic initiatives.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
